Nicola Brownlow

List of Publications by Year
in descending order

12	256	1163117 8	1199594 12
papers	citations	h-index	g-index

13	13	13	511
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Aurora B specificity switch is required to protect from non-disjunction at the metaphase/anaphase transition. Nature Communications, 2020, 11, 1396.	12.8	12
2	<scp>STAT</scp>4 expression and activation is increased during mitosis in vitro and in vivo in skinâ€•and mucosaâ€derived cell types: implications in neoplastic and inflammatory skin diseases. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1663-1673.	2.4	4
3	DNA replication stress: NoCut to the rescue. Cell Cycle, 2017, 16, 233-234.	2.6	7
4	PKCÉ› switches Aurora B specificity to exit the abscission checkpoint. Nature Communications, 2016, 7, 13853.	12.8	21
5	Mitotic catenation is monitored and resolved by a PKCÎµ-regulated pathway. Nature Communications, 2014, 5, 5685.	12.8	21
6	Regulation of the cytokinesis cleavage furrow by PKCÎµ. Biochemical Society Transactions, 2014, 42, 1534-1537.	3.4	5
7	Novel Imatinib Derivatives with Altered Specificity between Bcrâ€“Abl and FMS, KIT, and PDGF Receptors. ChemMedChem, 2010, 5, 130-139.	3.2	17
8	Protein kinase C epsilon in cell division: Control of abscission. Cell Cycle, 2009, 8, 549-555.	2.6	16
9	Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia, 2009, 23, 590-594.	7.2	59
10	Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia, 2008, 22, 649-652.	7.2	32
11	Tandutinib inhibits FMS receptor signalling, and macrophage and osteoclast formation in vitro. Leukemia, 2008, 22, 1452-1453.	7.2	6
12	FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene, 2006, 25, 147-151.	5.9	56